Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegfilgrastim-bmez
- Development stage
- Approved
- Lead developer
- Sandoz
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Pegfilgrastim-bmez is a biosimilar of pegfilgrastim, marketed under the brand name Ziextenzo. It is a long-acting, recombinant human granulocyte colony-stimulating factor (G-CSF) analog used to reduce the risk of infection in patients with non-myeloid cancers receiving myelosuppressive chemotherapy and to treat acute radiation syndrome. Pegfilgrastim-bmez stimulates the bone marrow to produce neutrophils by binding to specific cell surface receptors on hematopoietic cells, promoting their proliferation, differentiation, and activation. This helps decrease the duration of severe neutropenia and lowers infection risk during cancer treatment or after radiation exposure[2][3][4].
- Brand names
- Ziextenzo
- Other names
- pegfilgrastim-bmezLA-EP2006LA-EP-2006LA-EP 2006Ziextenzo
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on pegfilgrastim-bmez.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegfilgrastim-bmez.